Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0171 + Durvalumab + Chemotherapy in Metastatic Pancreatic Cancer
NCT04999969Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Countries
- 4
01
Overview
A Phase 2 trial of AZD0171 in pancreatic ductal adenocarcinoma (PDAC), sponsored by AstraZeneca. Started Dec 2021; status: active, not recruiting.
02
Drugs
AZD0171
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04999969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999969.